Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular protection and should be prioritized in women with type 2 diabetes and high cardiovascular risk.
If you have diabetes and heart risk factors, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs protect your heart and kidneys beyond just lowering blood sugar. Standard sugar-lowering pills may not be enough for heart protection.
StrongSupportsVERY_HIGH confidence
The use of pharmacological therapy to address these risk factors, especially some pleiotropic antihyperglycemic drugs, may provide additional options for the prevention of cardiovascular disease.
Why this rating
Supported by multiple large RCTs (EMPA-REG, CANVAS, DECLARE, LEADER, SUSTAIN-6) cited in the text.
Source
Principles of cardiovascular risk management in perimenopausal women with type 2 diabetes
Ф. О. Ушанова et al. · FOCUS Endocrinology · 2023
DOI 10.15829/1560-4071-2023-22
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Menopausal hormone therapy (MHT) containing estrogen does not reduce cardiovascular disease risk and may increase stroke risk in women with type 2 diabetes, making it unsuitable for primary prevention.Good
- Lifestyle modification (smoking cessation, diet, exercise) is the fundamental basis for managing cardiovascular risk in perimenopausal women with type 2 diabetes, though long-term weight maintenance is difficult.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →